Carbonic anhydrase inhibitors and the management of cancer

Current Topics in Medicinal Chemistry

Volumn 7, Issue 9, 2007, Pages 865-878

  Pastorekova, Silvia ^a   Kopacek, Juraj ^a   Pastorek, Jaromir ^a  

^a INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; CARBONATE DEHYDRATASE XII; DENDRITIC CELL VACCINE; DICLOFENAMIDE; DOXORUBICIN; ETHOXZOLAMIDE; FLUORESCEIN; FLUORESCEIN ISOTHIOCYANATE; IDIOTYPIC ANTIBODY; METHAZOLAMIDE; MONOCLONAL ANTIBODY G250; SULFANILAMIDE DERIVATIVE; SULFONAMIDE; THIOUREIDOHOMOSULFANILAMIDE; UNCLASSIFIED DRUG;

ACIDOSIS; ANTINEOPLASTIC ACTIVITY; CANCER; CARCINOGENESIS; CATALYSIS; CELL SURVIVAL; DIAGNOSTIC IMAGING; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME REGULATION; HUMAN; HYPOXIA; KIDNEY CARCINOMA; NEUTRON CAPTURE THERAPY; NONHUMAN; PHYSIOLOGICAL STRESS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; PROTEIN ISOFORMS;

EID: 34249670767     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780636708     Document Type: Review

References (176)

1. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2, 38-47.
2. Stubbs, M.; McSheehy, P. M. J.; Griffiths, J. R.; Bashford, C. L. Causes and consequences of tumor acidity and implications for treatment. Mol. Med. Today 2000, 6, 15-19.
3. Raghunand, N.; He, X.; van Sluis, R.; Mahoney, B.; Baggett, B.; Taylor, C.; Paine-Murrieta, G.; Roe, D.; Bhujwalla, Z. M.; Gillies, R. J. Enhancement of chemotherapy by manipulation of tumor pH. Br. J. Cancer 1999, 80, 1005-11.
4. Supuran, C. T. Carbonic anhydrases: Catalytic mechanisms, distribution and physiological roles. In: Carbonic Anhydrase: Its Inhibitors and Activators. C. T. Supuran; A. Scozzafava; J. Conway (Eds), 2004, pp. 1-24, CRC Press Boca Raton-London-New York-Washington D.C.
5. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J. Enz. Inhib. Med. Chem. 2004, 19, 199-229.
6. Nishimori, I. Acatalytic CAs: Carbonic anhydrase-related proteins. In: Carbonic Anhydrase: Its Inhibitors and Activators. C. T. Supuran; A. Scozzafava; J. Conway (Eds). 2004, pp. 25-44, CRC Press Boca Raton-London-New York-Washington D.C.
7. Peles, E.; Nativ, M.; Campbell, P. L.; Sakurai, T.; Martinez, R.; Lev, S.; Clary, D. O.; Schilling, J.; Barnea, G.; Plowman, G. D.; Grumet, M.; Schlessinger, J. The carbonic anhydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal cell recognition molecule contactin. Cell 1995, 82, 251-60.
8. Mori, M.; Staniunas, R. J.; Barnard, G. F.; Jessup, J. M.; Steele, G. D. Jr.; Chen, L. B. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology 1993, 105, 820-826.
9. Kivela, A. J.; Saarnio, J.; Karttunen, T. J.; Kivela, J.; Parkkila, A. K.; Pastorekova, S.; Pastorek, J.; Waheed, A.; Sly, W. S.; Parkkila, T. S.; Rajaniemi, H. Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors. Dig. Dis. Sci. 2001, 46, 2179-2186.
10. Chiang, W. L.; Chu, S. C.; Yang, S. S.; Li, M. C.; Lai, J. C.; Yang, S. F.; Chiou, H. L.; Hsieh, Y. S. The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer. Cancer Lett. 2002, 188, 199-205.
11. Kuo, W. H.; Chiang, W. L.; Yang, S. F.; Yeh, K. T.; Yeh, C. M.; Hsieh, Y. S.; Chu, S. C. The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci. 2003, 73, 2211-2223.
12. Kummola, L.; Hamalainen, J. M.; Kivela, J.; Kivela, A. J.; Saarnio, J.; Karttunen, T.; Parkkila, S. Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer 2005, 5, 41.
13. Akisawa, Y.; Nishimori, I.; Taniuchi, K.; Okamoto, N.; Takeuchi, T.; Sonobe, H.; Ohtsuki, Y.; Onishi, S. Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer. Virchows Arch. 2003, 442, 66-70.
14. Miyaji, E.; Nishimori, I.; Taniuchi, K.; Takeuchi, T.; Ohtsuki, Y.; Onishi, S. Overexpression of carbonic anhydrase-related protein VIII in human colorectal cancer. J. Pathol. 2003, 201, 37-45.
15. Lu, S. H.; Takeuchi, T.; Fujita, J.; Ishida, T.; Akisawa, Y.; Nishimori, I.; Kohsaki, T.; Onishi, S.; Sonobe, H.; Ohtsuki, Y. Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth. Lung Cancer 2004, 44, 273-280.
16. Pastorekova, S.; Zavadova, Z.; Kostal, M.; Babusikova, O.; Zavada, J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992, 187, 620-626.
17. Zavada, J.; Zavadova, Z.; Pastorekova, S.; Ciampor, F.; Pastorek, J.; Zelnik, V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int. J. Cancer 1993, 54, 268-274.
18. Liao, S. Y.; Brewer, C.; Zavada, J.; Pastorek, J.; Pastorekova, S.; Manetta, A.; Berman, M. L.; DiSaia, P. J.; Stanbridge, E. J. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am. J. Pathol. 1994, 145, 598-609.
19. Pastorek, J.; Pastorekova, S.; Callebaut, I.; Mornon, J.-P.; Zelnik, V.; Opavsky, R.; Zatovicova, M.; Liao, S.; Portetelle, D.; Stanbridge, E.; Zavada, J.; Burny, A.; Kettmann, R. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 1994, 9, 2877-2888.
20. Opavsky, R.; Pastorekova, S.; Zelnik, V.; Gibadulinova, A.; Stanbridge, E. J.; Zavada, J.; Kettmann, R.; Pastorek, J. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics 1996, 33, 480-487
21. Hewett-Emmett, D.; Tashian, R.E. Functional diversity, consrevation and convergence in the evolution of the alpha, beta and gamma carbonic anhydrase gene families. Mol. Phyl. Evol. 1996, 5, 50-77.
22. Zavada, J.; Zavadova, Z.; Pastorek, J.; Biesova, Z.; Jezek, K.; Velek, J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br. J. Cancer 2000, 82, 1808-1813.
23. Svastova, E.; Zilka, N.; Zatovicova, M.; Gibadulinova, A.; Ciampor, F.; Pastorek, J.; Pastorekova, S. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin. Exp. Cell Res. 2003, 290, 332-345
24. Krueger, N.X.; Saito, H. A human transmembrane protein-tyrosinephosphatase, PTP zeta, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases. Proc. Natl. Acad. Sci. USA 1992, 89, 7417-7421.
25. Barnea, G.; Grumet, M.; Milev, P.; Silvennoinen, O.; Levy, J. B.; Sap, J.; Schlessinger, J. Receptor tyrosine phosphatase beta is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin. J. Biol. Chem. 1994, 269, 14349-14352
26. Dorai, T.; Sawczuk, I. S.; Pastorek, J.; Wiernik, P. H.; Dutcher, J. P. Biological significance of overexpression of carbonic anhydrase IX in renal cell carcinoma: EGF-induced phosphorylation of carbonic anhydrase IX leads to activation of PI-3-kinase pathway in renal cell carcinoma. Eur. J. Cancer 2005, 41, 2935-2947.
27. Pastorekova, S.; Parkkila, S.; Parkkila, A. K.; Opavsky, R.; Zelnik, V.; Saarnio, J.; Pastorek, J. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementery DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997, 112, 398-408.
28. Saarnio, J.; Parkkila, S.; Parkkila, A.-K.; Waheed, A.; Casey, M. C.; Zhou, X. Y.; Pastorekova, S.; Pastorek, J.; Karttunen, T.; Haukipuro, K.; Kairaluoma, M. I.; Sly, W. S. Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J. Histochem. Cytochem. 1998, 46, 497-504.
29. Gut, M.O.; Parkkila, S.; Vernerova, Z.; Rohde, E.; Zavada, J.; Hocker, M.; Pastorek, J.; Karttunen, T.; Zavadova, Z.; Knobeloch, K. P.; Wiedenmann, B.; Svoboda, J.; Horak, I.; Pastorekova, S. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002, 123, 1889-1903
30. Ivanov, S.; Liao, S. Y.; Ivanova, A.; Danilkovich-Miagkova, A.; Tarasova, N.; Weirich, G.; Merrill, M. J.; Proescholdt, M. A.; Oldfield, E. H.; Lee, J.; Zavada, J.; Waheed, A.; Sly, W. S.; Lerman, M. I.; Stanbridge, E. J. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 2001, 158, 905-919.
31. Karhumaa, P.; Kaunisto, K.; Parkkila, S.; Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly, W. S.; Rajaniemi, H. Expression of the transmembrane Carbonic Anhydrase Inhibitors and the Management of Cancer Current Topics in Medicinal Chemistry, 2007, Vol. 7, No. 9 875 carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts. Mol. Hum. Reprod. 2001, 7, 611-616.
32. Liao, S. Y.; Aurelio, O. N.; Jan, K.; Zavada, J.; Stanbridge, E. J. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 1997, 57, 2827-2831.
33. McKiernan, J.M.; Buttyan, R.; Bander, N. H.; Stifelman, M. D.; Katz, A. E.; Olsson, C. A.; Sawczuk, I. S. Expression of the tumour-associated gene MN: A potential biomarker for human renal cell carcinoma. Cancer Res. 1997, 57, 2362-2365.
34. Turner, J. R.; Odze, R. D.; Crum, C. P.; Resnick, M. B. MN antigen expression in normal, preneoplastic and neoplastic esophagus: A clinicopathological study of a new cancer-associated biomarker. Hum. Pathol. 1997, 28, 740-744.
35. Vermylen, P.; Roufosse, C.; Burny, A.; Verhest, A.; Bossehaerts, T.; Pastorekova, S.; Ninane, V.; Sculier, J. P. Carbonic anhydrase IX antigen differentiates between preneoplastic and malignant lesions in non-small cell lung carcinomas. Eur. Respir. J. 1999, 14, 806-811.
36. Bartosova, M.; Parkkila, S.; Pohlodek, K.; Karttunen, T. J.; Galbavy, S.; Mucha, V.; Harris, A. L.; Pastorek, J.; Pastorekova, S. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and related to overexpression of c-erbB2. J. Pathol. 2002, 197, 1-8.
37. Saarnio, J.; Parkkila, S.; Parkkila, A. K.; Haukipuro, K.; Pastorekova, S.; Pastorek, J.; Kairaluoma, M. I., Karttunen, T. J. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol. 1998, 153, 279-285.
38. Haapasalo, J.; Nordfors, K.; Hilvo, M.; Rantala, I.; Soini, Y.; Parkkila, A. K.; Pastorekova, S.; Pastorek, J.; Parkkila, S.; Haapasalo, H. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin. Cancer Res. 2005, 12, 473-477
39. Kowalewska, M.; Radziszewski, J.; Kulik, J.; Barathova, M.; Nasierowska-Guttmajer, A.; Bidzinski, M.; Pastorek, J.; Pastorekova, S.; Siedlecki, J. A. Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR. Int. J. Cancer 2005, 116, 957-962.
40. Kaluz, S.; Kaluzova, M.; Opavsky, R.; Pastorekova, S.; Gibadulinova, A.; Dequiedt, F.; Kettmann, R.; Pastorek, J. Transcriptional regulation of the MN/CA9 gene coding for the tumor-associated carbonic anhydrase IX. Identification and characterization of a proximal silencer element. J. Biol. Chem. 1999, 274, 32588-32595.
41. Kaluzova, M.; Pastorekova, S.; Svastova, E.; Pastorek, J.; Stanbridge, E. J.; Kaluz, S. Characterization of the MN/CA9 proximal region: A role for SP and AP1 factors. Biochem. J. 2001, 359, 669-677.
42. Wykoff, C.; Beasley, N.; Watson, P.; Turner, L.; Pastorek, J.; Wilson, G.; Turley, H.; Maxwell, P.; Pugh, C.; Ratcliffe, P.; Harris, A. Hypoxia-inducible regulation of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075-7083.
43. Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.; Salic, A.; Asara, J. M.; Lane, W. S.; Kaelin, W. G. HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 2001, 292, 464-468.
44. Jaakkola, P.; Mole, D. R.; Tian, Y. M.; Wilson, M. I.; Gielbert, J.; Gaskell, S. J.; von Kriegsheim, A.; Heberstreist, H. F.; Mukherji, M.; Schofield, C. J.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J. Targeting of HIFα to the von Hippel Lindau ubiquitilation complex by O2-regulated prolyl hydroxylation. Science 2001, 292, 468-472.
45. Mahon, P. C.; Hirota, K.; Semenza, G. L. FIH-1: A novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 2001, 15, 2675-2686.
46. Semenza, G. L. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 2002, 64, 993-998.
47. Bardos, J.; Ashcroft, M. Hypoxia-inducible factor-1 and oncogenic signaling. BioEssays 2004, 26, 262-269.
48. Laughner, E.; Taghavi, P.; Chiles, K.; Mahon, P. C.; Semenza, G. L. HER2(neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 2001, 21, 3995-4004.
49. Richard, D. E.; Berra, E.; Gothie, E.; Roux, D.; Pouyssegur, J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 1999, 274, 32631-32637.
50. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3, 721-732.
51. Kaluz, S.; Kaluzova, M.; Stanbridge, E. J. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res. 2003, 63, 917-922.
52. Kaluz, S.; Kaluzova, M.; Chrastina, A.; Olive, P. L.; Pastorekova, S.; Pastorek, J.; Lerman, M. I.; Stanbridge, E. J. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1α stabilization : A role for phosphatidylinositol 3′-kinase. Cancer Res. 2002, 62, 4469-4477.
53. Kopacek, J.; Barathova, M.; Dequiedt, F.; Sepelakova, J.; Kettmann, R.; Pastorek, J.; Pastorekova, S. MAPK pathway contributes to density- and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX. Biochim. Biophys. Acta 2005, 1729, 41-49.
54. Iwai, K.; Yamanaka, K.; Kamura, T.; Minato, N.; Conaway, R. C.; Conaway, J. W.; Klausner, R. D.; Pause, A. Identification of the von Hippel-Lindau tumor-suppressor protein as a part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. USA 1999, 96, 12436-12441.
55. Lisztwan, J.; Imbert, G.; Wirbelauer, C.; Gstaiger, M.; Krek, W. The von Hippel-Lindau tumor suppressor is a component of a E3 ubiquitin-protein ligase activity. Genes Dev. 1999, 13, 1822-1833
56. Gnarra, J. R.; Tory, K.; Weng, Y.; Schmidt, L.; Wei, M. H.; Li, H.; Latif, F.; Liu, S.; Chen, F.; Duh, F. M.; Lubensky, I.; Duan, D. R.; Florence, C.; Pozzatti, R.; Walther, M. M.; Bander, N. H.; Grossmann, H. B.; Branch, H.; Pomer, S.; Brooks, J. D.; Isaacs, W. B.; Lerman, M. I.; Zbar, B.; Lineham, W. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Gene. 1994, 7, 85-90.
57. Ihnatko, R.; Kubes, M.; Takacova, M.; Sedlakova, O.; Sedlak, J.; Pastorek, J.; Kopacek, J.; Pastorekova, S. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int. J. Oncol. 2006, 29, 1925-1033.
58. Ashida, S.; Nishimori, I.; Tanimura, M.; Onishi, S.; Shuin, T. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J. Cancer Res. Clin. Oncol. 2002, 128, 561-568.
59. Jakubickova, L.; Biesova, Z.; Pastorekova, S.; Kettmann, R.; Pastorek, J. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. Int. J. Oncol. 2005, 26, 1121-1127.
60. Rafajova, M.; Zatovicova, M.; Kettmann, R.; Pastorek, J.; Pastorekova, S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int. J. Oncol. 2004, 24, 995-1004.
61. Zavada, J.; Zavadova, Z.; Zatovicova, M.; Hyrsl, L.; Kawaciuk, I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br. J. Cancer 2003, 89, 1067-1071.
62. Zatovicova, M.; Sedlakova, O.; Svastova, E.; Ohradanova, A.; Ciampor, F.; Arribas, J.; Pastorek, J.; Pastorekova, S. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br. J. Cancer 2005, 93, 1267-1276
63. Türeci, O.; Sahin, U.; Vollmar, E.; Siemer, S.; Göttert, E.; Seitz, G.; Parkkila, A. K.; Shah, G. N.; Grubb, J. H.; Pfreundschuh, M.; Sly, W. S. Human carbonic anhydrase XII: CDNA cloning, expression and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cancers. Proc. Natl. Acad. Sci. USA 1998, 95, 7608-7613.
64. Ivanov, S. V.; Kuzmin, I.; Wei, M. H.; Pack, S.; Geil, L.; Johnson, B. E., Stanbridge, E. J.; Lerman, M. I. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA 1998, 95, 12596-12601.
65. Karhumaa, P.; Parkkila, S.; Tureci, O.; Waheed, A.; Grubb, J. H.; Shah, G.; Parkkila, A. K.; Kaunisto, K.; Tapanainen, J.; Sly, W. S.; Rajaniemi, H. Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium. Mol. Hum. Reprod. 2000, 6, 68-74.
66. Hynninen, P.; Hamalainen, J. M.; Pastorekova, S.; Pastorek, J.; Waheed, A.; Sly, W. S.; Tomas, E.; Kirkinen, P.; Parkkila, S. Transmembrane carbonic anhydrase isozymes IX and XII in the female mouse reproductive tract. Reprod. Biol. Endocrinol. 2004, 2, 73.
67. Kivela, A.; Parkkila, S.; Saarnio, J.; Karttunen, T. J.; Kivela, J.; Parkkila, A. K.; Waheed, A.; Sly, W. S.; Grubb, J. H.; Shah, G.; Tureci, O.; Rajaniemi, H. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am. J. Pathol. 2000, 156, 577-584.
68. Parkkila, S.; Parkkila, A. K.; Saarnio, J.; Kivela, J.; Karttunen, T. J.; Kaunisto, K.; Waheed, A.; Sly, W. S.; Tureci, O.; Virtanen, I.; Rajaniemi, H. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J. Histochem. Cytochem. 2000, 48, 1601-1608.
69. Liao, S. Y.; Ivanov, S.; Ivanova, A.; Ghosh, S.; Cote, M. A.; Keefe, K.; Coca-Prados, M.; Stanbridge, E. J.; Lerman, M. I. Expression of cell surface transmembrane carbonic anhydrase genes CA9 and CA12 in the human eye: Overexpression of CA12 (CAXII) in glaucoma. J. Med. Genet. 2003, 40, 257-261.
70. Kyllonen, M. S.; Parkkila, S.; Rajaniemi, H.; Waheed, A.; Grubb, J. H.; Shah, G. N.; Sly, W. S.; Kaunisto, K. Localization of carbonic anhydrase XII to the basolateral membrane of H+-secreting cells of mouse and rat kidney. J. Histochem. Cytochem. 2003, 51, 1217-1224.
71. Whittington, D. A.; Waheed, A.; Ulmasov, B.; Shah, G. N.; Grubb, J. H.; Sly, W. S.; Christianson, D. W. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc. Natl. Acad. Sci. USA 2001, 98, 9545-9550.
72. Wingo, T.; Tu, C.; Laipis, P. J.; Silverman, D. N. The catalytic properties of human carbonic anhydrase IX. Biochem. Biophys. Res. Commun. 2001, 288, 666-669.
73. Ulmasov, B.; Waheed, A.; Shah, G. N.; Grubb, J. H.; Sly, W. S.; Tu, C.; Silverman, D. N. Purification and kinetic analysis of recombinant CA XII, a membrane carbonic anhydrase overexpressed in certain cancers. Proc. Natl. Acad. Sci. USA 2000, 97, 14212-14217.
74. Helmlinger, G.; Yuan, F.; Dellian, M.; Jain, R. K. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat. Med. 1997, 3, 177-182.
75. Sterling, D.; Reithmeier, R. A.; Casey, J. R. A transport metabolon. Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers. J. Biol. Chem. 2001, 276, 47886-47894
76. - exchanger binds carbonic anhydrase IV. J. Biol. Chem. 2002, 277, 25239-25246.
77. Alvarez, B. V.; Loiselle, F. B.; Supuran, C. T.; Schwartz, G. J.; Casey, J. R. Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemistry 2003, 42, 12321-12329.
78. Vince, J. W.; Reithmeier, R. A. Identification of the carbonic anhydrase II binding site in the Cl-/HCO3- anion exchanger AE1. Biochemistry 2000, 39, 5527-5533.
79. Scozzafava, A.; Supuran, C. T. Carbonic anhydrase activators: Hunam isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1. Bioorg. Med. Chem. Lett. 2002, 12, 1177-1180.
80. Karumanchi, S. A.; Jiang, L.; Knebelmann, B.; Stuart-Tilley, A. K.; Alper, S. L.; Sukhatme, V. P. VHL tumor suppressor regulates CL-/HCO3+ exchange and Na+/H+ exchange activities in renal carcinoma cells. Physiol. Genomics 2001, 5, 119-128.
81. Morgan, P. E.; Pastorekova, S.; Casey, J. R. Functional and physical interaction between bicarbonate transport proteins and the transmembrane carbonic anhydrase, CA IX. XXV. International Congress of Physiological Sciences, March 31-April 5 2005, San Diego, CA, Abstract No 366.5
82. Svastova, E.; Hulikova, A.; Rafajova, M.; Zat'ovicova, M.; Gibadulinova, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C. T.; Pastorek, J.; Pastorekova, S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577, 439-495.
83. Robertson, N.; Potter, C.; Harris, A. L. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 2004, 64, 6160-6165.
84. Zavadova, Z.; Zavada, J. Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment. Oncol. Rep. 2005, 13, 977-82.
85. Beavon, I. R. G. Regulation of E-cadherin: Does hypoxia initiate the metastatic cascade? J. Clin. Pathol. Mol. Pathol. 1999, 52, 179-188.
86. Wiesener, M. S.; Munchenhagen, P. M.; Berger, I.; Morgan, N. V.; Roigas, J.; Schwiertz, A.; Jurgensen, J. S.; Gruber, G.; Maxwell, P. H.; Loning, S. A.; Frei, U.; Maher, E. R.; Grone, H. J.; Eckardt, K. U. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas. Cancer Res. 2001, 61, 5215-5222.
87. Mandriota, S. J.; Tumer, K. J.; Davies, D. R.; Murray, P. G.; Morgan, N. V.; Sowter, H. M.; Wykoff, C. C.; Maher, E. R.; Harris, A. L.; Ratcliffe, P. J.; Maxwell, P. H. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1, 459-468.
88. Raval, R. R.; Lau, K. W.; Tran, M. G. B.; Sowter, H. M.; Mandriota, S. J.; Li, J. L.; Pugh, C. W.; Maxwell, P. H.; Harris, A. L.; Ratcliffe, P. J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell Biol. 2005, 25, 5675-5686.
89. Bui, M. H.; Seligson, D.; Han, K. R.; Pantuck, A. J.; Dorey, F. J.; Huang, Y.; Horvath, S.; Leibovich, B. C.; Chopra, S.; Liao, S. Y.; Stanbridge, E. J.; Lerman, M. I.; Palotie, A.; Figlin, R. A.; Belldegrun, A. S. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin. Cancer Res. 2003, 9, 802-811.
90. Bui, M. H.; Visapaa, H.; Seligson, D.; Kim, H.; Han, K. R.; Huang, Y.; Horvath, S.; Stanbridge, E. J.; Palotie, A.; Figlin, R. A.; Belldegrun, A. S. Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma. J. Urol. 2004, 171, 2461-2466.
91. Brouwers, A. H.; Frielink, C.; Oosterwijk, E.; Oyen, W. J.; Corstens, F. H.; Boerman, O. C. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio) immunotherapy of renal cell carcinoma. Cancer Biother. Radiopharm. 2003, 18, 539-547.
92. Atkins, M.; Regan, M.; McDermott, D.; Mier, J.; Stanbridge, E.; Youmans, A.; Febbo, P.; Upton, M.; Lechpammer, M.; Signoretti, S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 2005, 11, 3714-3721.
93. Pantuck, A. J.; Zeng, G.; Belldegrun, A. S.; Figlin, R. A. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin. Cancer Res. 2003, 9, 4641-4652.
94. Soyupak, B.; Erdogan, S.; Ergin, M.; Seydaoglu, G.; Kuzgunbay, B.; Tansug, Z. CA9 expression as a prognostic factor in renal clear cell carcinoma. Urol. Int. 2005, 74, 68-73.
95. Loncaster, J. A.; Harris, A. L.; Davidson, S. E.; Logue, J. P.; Hunter, R. D.; Wykoff, C. C.; Pastorek, J.; Ratcliffe, P.; Stratford, I. J.; West, C. M. L. Carbonic anhydrase IX expression, a potential new intrinsic marker of hypoxia: Correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001, 61, 6394-6399.
96. Olive, P. L.; Aquino-Parsons, C.; MacPhail, S. H.; Laio, S. Y.; Raleigh, J. A.; Lerman, M. I.; Stanbridge, E. J. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res. 2001, 61, 8924-8929.
97. Airley, R. E.; Loncaster, J.; Raleigh, J. A.; Harris, A. L.; Davidson, S. E.; Hunter, R. D.; West, C. M. L.; Stratford, I. J. GLUT-1 and CA IX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. Int. J. Cancer 2003, 104, 85-91.
98. Wykoff, C. C.; Beasley, N.; Watson, P. H.; Campo, L.; Chia, S. K.; English, R.; Pastorek, J.; Sly, W. S.; Ratcliffe, P.; Harris, A. L. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 2001, 158, 1011-1019.
99. Chia, S. K.; Wykoff, C. C.; Watson, P. H.; Han, C.; Leek, R. D.; Pastorek, J.; Gatter, K. C.; Ratcliffe, P.; Harris, A. L. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J. Clin. Oncol. 2001, 19, 3660-3668.
100. Giatromanolaki, A.; Koukourakis, M. I.; Sivridis, E.; Pastorek, J.; Wykoff, C. C.; Gatter, K. C.; Harris, A. L. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001, 61, 7992-7998.
101. Beasley, N. J. P.; Wykoff, C. C.; Watson, P. H.; Leek, R.; Turley, H.; Gatter, K.; Pastorek, J.; Cox, G. J.; Ratcliffe, P. J.; Harris, A. L. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis and microvessel density. Cancer Res. 2001, 61, 5262-5267.
102. Ord, J. J.; Streeter, E. H.; Roberts, I. S.; Cranston, D.; Harris, A. L. Comparison of hypoxia transcriptiome in vitro with in vivo gene expression in human bladder cancer. Br. J. Cancer 2005, 93, 346-354.
103. Tumer, K. J.; Crew, J. P.; Wykoff, C. C.; Watson, P. H.; Poulsom, R.; Pastorek, J.; Ratcliffe, P. J.; Cranston, D.; Harris, A. L. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br. J. Cancer 2002, 86, 1276-1282.
104. Hui, E. P.; Chan, A. T.; Pezzella, F.; Turley, H.; To, K. F.; Poon, T. C.; Zee, B.; Mo, F.; Teo, P. M.; Huang, D. P.; Gatter, K. C.; Johnson, P. J.; Harris, A. L. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res. 2002, 8, 2595-2604.
105. Hoskin, P. J.; Sibtain, A.; Daley, F. M.; Wilson, G. D. GLUT1 and CA IX as intrinsic markers of hypoxia in bladder cancer: Relationship with vascularity and proliferation as predictors of outcome of ARCON. Br. J. Cancer 2003, 89, 1290-1297.
106. Swinson, D. E.; Jones, J. L.; Cox, G.; Richardson, D.; Harris, A. L.; O'Byrne, K. J. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. Int. J. Cancer 2004, 111, 43-50.
107. Hutchison, G. J.; Valentine, H. R.; Loncaster, J. A.; Davidson, S. E.; Hunter, R. D.; Roberts, S. A.; Harris, A. L.; Stratford, I. J.; Price, P. M.; West, C. M. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin. Cancer Res. 2004, 10, 8405-8412.
108. Vleugel, M. M.; Greijer, A. E.; Shvarts, A.; van der Groep, P.; van Berkel, M.; Aarbodem, Y.; van Tinteren, H.; Harris, A. L.; van Diest, P. J.; van der Wall, E. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J. Clin. Pathol. 2005, 58, 172-177.
109. De Schutter, H.; Landuyt, W.; Verbeken, E.; Goethals, L.; Hermans, R.; Nuyts, S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005, 5, 42.
110. Kim, S. J.; Rabbani, Z. N.; Dewhirst, M. W.; Vujaskovic, Z.; Vollmer, R. T.; Schreiber, E. G.; Oosterwijk, E.; Kelley, M. J. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 2005, 49, 325-335.
111. Sorensen, B. S.; Hao, J.; Overgaard, J.; Vorum, H.; Honore, B.; Alsner, J.; Horsman, M. R. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother. Oncol. 2005, 76, 187-193.
112. Vordermark, D.; Kaffer, A.; Riedl, S.; Katzer, A.; Flentje, M. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 1197-1207.
113. Fukumura, D.; Xu, L.; Chen, Y.; Gohongi, T.; Seed, B.; Jain, R. K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 2001, 61, 6020-6024.
114. Colpaert, C. G.; Vermeulen, P. B.; Van Beest, P.; Soubry, A.; Goovaerts, G.; Dirix, L. Y.; Harris, A. L.; Van Marck, E. A. Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology 2003, 42, 530-540.
115. Span, P. N.; Bussink, J.; Manders, P.; Beex, L. V.; Sweep, C. G. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: Association with treatment outcome. Br. J. Cancer 2003, 89, 271-276.
116. Swinson, D. E.; Jones, J. L.; Richardson, D.; Wykoff, C.; Turley, H.; Pastorek, J.; Taub, N.; Harris, A. L.; O'Byrne, K. J. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J. Clin. Oncol. 2003, 21, 473-482.
117. Kim, S. J.; Rabbani, Z. N.; Vollmer, R. T.; Schreiber, E. G.; Oosterwijk, E.; Dewhirst, M. W.; Vujaskovic, Z.; Kelley, M. J. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 7925-7933.
118. Koukourakis, M. I.; Giatromanolaki, A.; Sivridis, E.; Simopoulos, K.; Pastorek, J.; Wykoff, C. C.; Gatter, K. C.; Harris, A. L. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer Res. 2001, 7, 3399-3403.
119. Hoogsteen, I. J.; Marres, H. A. M.; Wijffels, K. I. E. M.; Rijken, P. F. J. W.; Peters, J. P. W.; van den Hoogen, F. J. A.; Oosterwijk, E.; van der Kogel, A. J.; Kaanders, J. H. A. M. Colocalization of Carbonic Anhydrase 9 Expression and Cell Proliferation in Human Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res. 2005, 11, 97-106.
120. Maseide, K.; Kandel, R. A.; Bell, R. S.; Catton, C. N.; O'Sullivan, B.; Wunder, J. S.; Pintilie, M.; Hedley, D.; Hill R. P. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin. Cancer Res. 2004, 10, 4464-4471.
121. Chen, J.; Röcken, C.; Hoffmann, J.;, Krüger, S.; Lendeckel, U.; Rocco, A.; Pastorekova, S.; Malfertheiner, P.; Ebert, M. P. A. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 2005, 54, 920-927.
122. Oosterwijk, E.; Ruiter, D. J.; Hoedemaeker, P. J.; Pauwels, E. K.; Jonas, U.; Zwartendijk, J.; Warnaar, S. O. Monoclonal antibody G250 recognizes determinant present in renal cell carcinoma and absent from normal kidney. Int. J. Cancer 1986, 38, 489-494
123. Grabmaier, K.; Vissers, J. L.; De Weijert, M. C.; Oosterwijk-Wakka, J. C.; Van Bokhoven, A.; Brakenhoff, R. H.; Noessner, E.; Mulders, P. A.; Merkx, G.; Figdor, C. G.; Adema, G. J.; Oosterwijk, E. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int. J. Cancer 2000, 85, 865-870.
124. Luiten, R. M.; Coney, L. R.; Fleuren, G. J.; Warnaar, S. O.; Litvinov, S. V. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Brit. J. Cancer 1996, 74, 735-744.
125. Luiten, R. M.; Warnaar, S. O.; Schuurman, J.; Pasmans, S. G.; Latour, S.; Daeron, M.; Fleuren, G. J.; Litvinov, S. V. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells. Hum. Antibodies 1997, 8, 169-180
126. Steffens, M. G.; Boerman, O. C.; Oyen, W. J.; Kniest, P. H.; Witjes, J. A.; Oosterhof, G. O.; van Leenders, G. J.; Debruyne, F. M.; Corstens, F. H.; Oosterwijk, E. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy. Cancer Res. 1999, 59, 1615-1619.
127. Vissers, J. L.; De Vries, I. J.; Schreurs, M. W.; Engelen, L. P.; Oosterwijk, E.; Figdor, C. G.; Adema, G. J. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 1999, 59, 5554-5559.
128. Uemura, H.; Okajima, E.; Debruyne, F. M. J.; Oosterwijk, E. Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int. J. Cancer 1994, 56, 609-614.
129. Uemura, H.; Beniers, A. J.; Okajima, E.; Debruyne, F. M. J.; Oosterwijk, E. Vaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity. Int. J. Cancer 1994, 58, 555-561.
130. Uemura, H.; Okajima, E.; Debruyne, F. M. J.; Oosterwijk, E. Anti-tumor effect induced by vaccination with anti-idiotype antibodies in 7 mice with established human renal cell carcinoma xenografts. Urol. Oncol. 1995, 1, 73-79.
131. Weijtens, M. E. M.; Willemsen, R. A.; Valerio, D.; Stam, K.; Bolhus, R. L. H. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle their lytic capacity. J. Immunol. 1996, 157, 836-843
132. Weijtens, M. E.; Willemsen, R. A.; van-Krimpen, B. A.; Bolhuis, R. L. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accesory molecules. Int. J. Cancer 1998, 77, 181-187.
133. Steffens, M. G.; Oosterwijk, E.; Zegwaart-Hagemeier, N. E.; van't Hof, M. A.; Debruyne, F. M.; Corstens, F. H.; Boerman, O. C. Immunohistochemical analysis of intratumoral heterogenity of [131 I] cG250 antibody uptake in primary renal cell carcinomas. Br. J. Cancer 1998, 78, 1208-1213.
134. Supuran, C. T.; Scozzafava, A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Patents 2000, 10, 575-600.
135. Supuran, C. T.; Briganti, F.; Tilli, S.; Chegwidden, W. R.; Scozzafava, A. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents? Bioorg. Med. Chem. Lett. 2001, 9, 703-714.
136. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin. Ther. Patents 2004, 14, 667-702
137. Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C.T. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2003, 13, 1005-1009.
138. Jaiswal, M.; Khadikar, P. V.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: The first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides. Bioorg. Med. Chem. Lett. 2004, 14, 3283-90.
139. Ozensoy, O.; Pucetti, L.; Fasolis, G.; Arslan, O.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isoenzymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg. Med. Chem. Lett. 2005, 15, 4862-4866.
140. Ilies, M. A.; Vullo, D.; Pastorek, J.; Scozzafava, A.; Ilies, M.; Caproiu, M. T.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenyl-aminobenzolamide derivatives. J. Med. Chem. 2003, 46, 2187-2196
141. Franchi, M.; Vullo, D.; Gallori, E.; Pastorek, J.; Russo, A.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides. J. Enzyme Inhib. Med. Chem. 2003, 18, 333-338.
142. Winum, J. Y.; Vullo, D.; Casini, A.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme IX with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors. J. Med. Chem. 2003, 46, 2197-2204.
143. Winum, J. Y.; Vullo, D.; Casini, A.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes 1 and II with aliphatic sulfamates. J. Med. Chem. 2003, 46, 5471-5477.
144. Vullo, D.; Scozzafava, A.; Pastorekova, S.; Pastorek, J.; Supuran, C. T. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg. Med. Chem. Lett. 2004, 14, 2351-2356.
145. Garaj, V.; Pucetti, L.; Fasolis, G.; Winum, J. Y.; Montero, J. L.; Scozzafava, A.; Vullo, D.; Innocenti, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg. Med. Chem. Lett. 2004, 14, 5427-5433.
146. Garaj, V.; Pucetti, L.; Fasolis, G.; Winum, J. Y.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX. Bioorg. Med. Chem. Lett. 2005, 15, 3102-3108.
147. Cecchi, A.; Winum, J. Y.; Innocenti, A.; Vullo, D.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato-benzolamide. Bioorg. Med. Chem. Lett. 2004, 14, 5775-5780.
148. Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 225-229.
149. Pucetti, L.; Fasolis, G.; Cecchi, A.; Winum, J. Y.; Gamberi, A.; Montero, J. L.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. Bioorg. Med. Chem. Lett. 2005, 15, 2359-64.
150. Turkmen, H.; Dugrun, M.; Yilmaztekin, S.; Emul, M.; Innocenti, A.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inibitors: novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II and the tumor-associated isozymes IX. Bioorg. Med. Chem. Lett. 2005, 17, 367-372.
151. Winum, J. Y.; Pastorekova, S.; Jakubickova, L.; Montero, J. L.; Scozzafava, A.; Pastorek, J.; Vullo, D.; Innocenti, A.; Supuran, C. T. Carbonic anhydrase inibitors: Synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II and IX with bis-sulfamates. Bioorg. Med. Chem. Lett. 2005, 15, 573-578.
152. Winum, J. Y.; Dogne, J. M.; Casini, A.; de Leval, X.; Montero, J. L.; Scozzafava, A.; Vullo, D.; Innocenti, A.; Supuran, C. T. Carbonic anhydrase inibitors: Synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II and IX with sulfonamides incorporating hydrazine moieties. J. Med. Chem. 2005, 48, 2121-2125.
153. Almajan, G. L.; Innocenti, A.; Pucetti, L.; Manole, G.; Berbuceanu, S.; Saramet, I.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inibitors: Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II and IX with a series of 1,3,4-thiadiazole- and 1,2,4-triazole-thiols. Bioorg. Med. Chem. Lett. 2005, 15, 2347-2352.
154. Winum, J. Y.; Innocenti, A.; Nasr, J.; Montero, J. L.; Scozzafava, A.; Vullo, D.; Supuran, C. T. Carbonic anhydrase inibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with N-hydroxysulfamides - a new zinc-binding function in the design of inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2353-2358.
155. Pastorekova, S.; Vullo, D.; Casini, A.; Scozzafava, A.; Pastorek, J.; Nishimori, I.; Supuran, C. T. Carbonic anhydrase inibitors: Synthesis and inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides. J. Enzyme Inhib. Med. Chem. 2005, 20, 211-217.
156. Innocenti, A.; Villar, R.; Martinez-Merino, V.; Gil, M. J.; Scozzafava, A.; Vullo, D.; Supuran, C. T. Carbonic anhydrase inibitors: Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with benzo[b]thiophene 1,1 dioxide sulfonamides. Bioorg. Med. Chem. Lett. 2005, 15, 4872-4876.
157. Cecchi, A.; Taylor, S. D.; Liu, Y.; Hill, B.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inibitors: Inhibition of the human isozymes I, II, VA and IX with a library of substituted difluoromethanesulfinamides. Bioorg. Med. Chem. Lett. 2005, 15, 5192-5196.
158. Thiry, A.; Ledecq, M.; Cecchi, A.; Dogne, J. M.; Wouters, J.; Supuran, C. T.; Masereel, B. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J. Med. Chem. 2006, 49, 2743-2749.
159. Casey, J. R.; Morgan, P. E.; Vullo, D.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J. Med. Chem. 2004, 47, 2337-2347.
160. Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C. T. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869-873
161. Vullo, D.; Franchi, M.; Gallori, E.; Pastorek, J.; Scozzafava, A.; Pastorekova, S.; Supuran, C. T. Carbonic anhydrase inhibitors. Interaction of cytosolic isozymes I and II and transmembrane cancer-associated isozyme IX with anions. J. Enzyme Inhib. Med. Chem. 2003, 18, 403-406.
162. Innocenti, A.; Vullo, D.; Scozzafava, A.; Casey, J. R.; Supuran, C. T. Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med. Chem. Lett. 2005, 15, 573-578.
163. Innocenti, A.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate and carbonate. Bioorg. Med. Chem. Lett. 2005, 15, 567-571.
164. Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastorekova, S.; Scozzafava, A.; Winum, J. Y.; Montero, J. L.; Supuran, C. T. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J. Med. Chem. 2005, 48, 4834-4841.
165. Xu, L.; Fidler, I. J. Acidic pH-induced elevation in interleukin 8 expression by human ovarian carcinoma cells. Cancer Res. 2000, 60, 4610-4616.
166. D'Arcangelo, D.; Facchiano, F.; Barlucchi, L. M.; Melillo, G.; Illi, B.; Testolin, L.; Gaetano, C.; Apogrossi, M. C. Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblast growth factor and vascular endothelial growth factor expression. Circ. Res. 1999, 86, 312-318.
167. Kato, Y.; Nakayama, Y.; Umeda, M.; Miyazaki, K. Induction of 103-kDa gelatinase/type IV collagenase by acidic culture conditions in mouse metastatic melanoma cell lines. J. Biol. Chem. 1992, 267, 11424-11430.
168. Martinez-Zaguilan, R.; Seftor, E. A.; Seftor, R. E.; Chu, Y. W.; Gillies, R. J.; Hendrix, M. J. Acidic pH enhances the invasive behavior of human melanoma cells. Clin. Exp. Metastasis 1992, 14, 176-186.
169. Reynolds, T. Y.; Rockwell, S.; Glazer, P. M. Genetic instability induced by the tumor microenvironment. Cancer Res. 1996, 56, 5754-5757.
170. Parkkila, S.; Rajaniemi, H.; Parkkila, A. K.; Kivela, J.; Waheed, A.; Pastorekova, S.; Pastorek, J.; Sly, W. S. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl. Acad. Sci. USA 2000, 97, 2220-2224.
171. Vukovic, V.; Tannock, I. F. Influence of the pH on cytotoxicity of paclitaxel, mitoxanthrone and topotecan. Br. J. Cancer 1997, 75, 1167-1172.
172. Raghunand, N.; Gatenby, R. A.; Gillies, R. J. Microenvironmental and cellular consequences of altered blood flow in tumors. Br. J. Radiol. 2003, 76, S11-S22.
173. Kozin, S. V.; Shkarin, P.; Gerweck, L. E. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res. 2001, 61, 4740-4743.
174. Gerweck, L. E. Tumor pH: Implications for treatment and novel drug design. Semin. Radiat. Oncol. 1998, 8, 176-182
175. Teicher, B. A.; Liu, S. D.; Liu, J. T.; Holden, S. A.; Herman, T. S. A carbonic anhydrase inhibitor is potential modulator of cancer therapies. Anticancer Res. 1993, 13, 1549-1556.
176. Winum, J. Y.; Cecchi, A.; Montero, J. L.; Innocenti, A.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II and IX with oron-containing sulfonamides, sulfamides and sulfamates: Towards agents for boron neutron capture therapy of hypoxic tumors. Bioorg. Med. Chem. Lett. 2005, 15, 3302-3306.